Andreas Recke, EAACI 2022: Lanadelumab in the Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency

The ENABLE study (ClinicalTrials.gov Identifier: NCT04130191) is an observational study, investigating the effectiveness of lanadelumab in real-life use in patients with hereditary angioedema with C1 inhibitor deficiency (HAE-C1-1NH). touchIMMUNOLOGY were delighted to speak with Dr. Andreas Recke (University of Lübeck, Lübeck, Germany) to discuss the aims, design and findings from his interim analysis of the ENABLE study. 

The abstract ‘Lanadelumab Treatment Patterns Among Patients With HAE-C1-INH: Interim Analysis of the ENABLE Study.’ was presented at EAACI 2022, 1-3 July, 2022.

Questions

1. What is the rationale for the use of lanadelumab in the treatment of HAE-C1-1NH? (0:25)
2. What clinical evidence to date supports the use of lanadelumab? (2:02)
3. What are the aims and design of the ENABLE study? (3:25)
4. What have the interim findings taught us about lanadelumab treatment patterns among patients with HAE-C1-INH? (4:13)

Disclosures: Andreas Recke has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the EAACI Hybrid Congress 2022.